Singh M et al. |
A comparison of biodegradable microparticles and MF59 as systemic adjuvants for recombinant gD from HSV-2. |
1998 |
Vaccine |
pmid:9795387
|
Podda A |
The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. |
2001 |
Vaccine |
pmid:11257408
|
Greer CE et al. |
The comparison of the effect of LTR72 and MF59 adjuvants on mouse humoral response to intranasal immunisation with human papillomavirus type 6b (HPV-6b) virus-like particles. |
2000 |
Vaccine |
pmid:11137233
|
Skeiky YA et al. |
Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant. |
2002 |
Vaccine |
pmid:12213399
|
Esposito S et al. |
Immunogenicity, safety and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in patients with β-thalassemia major. |
2010 |
Vaccine |
pmid:20888873
|
Camilloni B et al. |
Cross-reactive antibodies in middle-aged and elderly volunteers after MF59-adjuvanted subunit trivalent influenza vaccine against B viruses of the B/Victoria or B/Yamagata lineages. |
2009 |
Vaccine |
pmid:19410623
|
Phillips CJ et al. |
Antibodies to squalene in US Navy Persian Gulf War veterans with chronic multisymptom illness. |
2009 |
Vaccine |
pmid:19379786
|
Carmona A et al. |
Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months. |
2010 |
Vaccine |
pmid:20600478
|
Frey SE et al. |
Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. |
2010 |
Vaccine |
pmid:20619382
|
Dell'Era L et al. |
Immunogenicity, safety and tolerability of MF59-adjuvanted seasonal influenza vaccine in children with juvenile idiopathic arthritis. |
2012 |
Vaccine |
pmid:22138210
|
Guillon C et al. |
Formulation of HIV-1 Tat and p24 antigens by PLA nanoparticles or MF59 impacts the breadth, but not the magnitude, of serum and faecal antibody responses in rabbits. |
2007 |
Vaccine |
pmid:17904700
|
Baldo V et al. |
MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications. |
2007 |
Vaccine |
pmid:17383057
|
Bråve A et al. |
Candidate HIV-1 gp140DeltaV2, Gag and Tat vaccines protect against experimental HIV-1/MuLV challenge. |
2007 |
Vaccine |
pmid:17707956
|
O'Hagan DT et al. |
Cationic microparticles are a potent delivery system for a HCV DNA vaccine. |
2004 |
Vaccine |
pmid:15542189
|
Faenzi E et al. |
One dose of an MF59-adjuvanted pandemic A/H1N1 vaccine recruits pre-existing immune memory and induces the rapid rise of neutralizing antibodies. |
2012 |
Vaccine |
pmid:22521851
|
Hatz C et al. |
A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations. |
2012 |
Vaccine |
pmid:22626675
|
Dey AK et al. |
Use of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoprotein. |
2012 |
Vaccine |
pmid:22366638
|
Yang WH et al. |
Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: an observer-blind, randomized trial. |
2013 |
Vaccine |
pmid:23856331
|
Calabro S et al. |
The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect. |
2013 |
Vaccine |
pmid:23684834
|
Segura-Velázquez R et al. |
Influenza vaccine: development of a novel intranasal and subcutaneous recombinant adjuvant. |
2013 |
Vaccine |
pmid:23746458
|